Daratumumab shots at home for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at whether people with multiple myeloma can safely give themselves daratumumab injections at home, instead of going to the hospital each time. You'll get the same medicine, but learn to manage it yourself with support, and share your experience through questionnaires and an interview.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma, a type of blood cancer.
- You are starting treatment with daratumumab given as a shot under the skin (not as an IV drip).
- You can read and understand Danish, and can fill out questionnaires and talk with the study team.
- Your doctor thinks it's safe and appropriate for you to give yourself the injection at home.
- You do not live on an island without a bridge, and you do not have other treatments that require a hospital visit on the same day as your at-home injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
This trial tests a new device called FreedomEDGE® that gives daratumumab under the skin instead of by an IV. It might make your monthly treatment faster and more comfortable.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.